CA2394027C - Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDF

Info

Publication number
CA2394027C
CA2394027C CA002394027A CA2394027A CA2394027C CA 2394027 C CA2394027 C CA 2394027C CA 002394027 A CA002394027 A CA 002394027A CA 2394027 A CA2394027 A CA 2394027A CA 2394027 C CA2394027 C CA 2394027C
Authority
CA
Canada
Prior art keywords
linear
branched
formula
pyrido
octahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002394027A
Other languages
English (en)
French (fr)
Other versions
CA2394027A1 (fr
Inventor
Solo Goldstein
Guillaume Poissonnet
Jean-Gilles Parmentier
Pierre Lestage
Brian Lockhart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CA2394027A1 publication Critical patent/CA2394027A1/fr
Application granted granted Critical
Publication of CA2394027C publication Critical patent/CA2394027C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002394027A 2001-07-12 2002-07-12 Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Expired - Fee Related CA2394027C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01.09260 2001-07-12
FR0109260A FR2827288B1 (fr) 2001-07-12 2001-07-12 Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
CA2394027A1 CA2394027A1 (fr) 2003-01-12
CA2394027C true CA2394027C (fr) 2008-01-08

Family

ID=8865405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002394027A Expired - Fee Related CA2394027C (fr) 2001-07-12 2002-07-12 Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Country Status (24)

Country Link
US (1) US6992085B2 (enExample)
EP (1) EP1275647B1 (enExample)
JP (1) JP3950018B2 (enExample)
KR (1) KR100485020B1 (enExample)
CN (1) CN1197863C (enExample)
AR (1) AR036166A1 (enExample)
AT (1) ATE254124T1 (enExample)
AU (1) AU2002300094B2 (enExample)
BR (1) BR0202681A (enExample)
CA (1) CA2394027C (enExample)
DE (1) DE60200089T2 (enExample)
DK (1) DK1275647T3 (enExample)
EA (1) EA005160B1 (enExample)
ES (1) ES2210219T3 (enExample)
FR (1) FR2827288B1 (enExample)
HU (1) HUP0202282A3 (enExample)
MX (1) MXPA02006699A (enExample)
NO (1) NO322966B1 (enExample)
NZ (1) NZ520120A (enExample)
PL (1) PL355034A1 (enExample)
PT (1) PT1275647E (enExample)
SI (1) SI1275647T1 (enExample)
TR (1) TR200302001T4 (enExample)
ZA (1) ZA200205596B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089410A1 (ja) * 2003-04-03 2004-10-21 Kyowa Hakko Kogyo Co., Ltd. 神経因性疼痛の予防及び／または治療剤
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1761267A1 (en) * 2004-06-22 2007-03-14 Pfizer Products Incorporated Diazabicyclic histamine-3 receptor antagonists
RU2442775C2 (ru) * 2005-07-04 2012-02-20 Хай Пойнт Фармасьютикалс, ЛЛС Антагонисты гистаминовых н3-рецепторов
EP2386554A1 (en) * 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
EP1998620B1 (en) * 2006-03-10 2011-01-12 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
KR100871691B1 (ko) 2006-10-16 2008-12-05 삼성전자주식회사 병렬 비트 테스트 방법 및 그 방법을 사용하는 반도체메모리 장치
JP7015092B2 (ja) 2016-07-28 2022-02-02 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
US11578084B2 (en) 2018-01-26 2023-02-14 Shionogi & Co., Ltd. Condensed ring compounds having dopamine D3 receptor antagonistic effect

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3388128A (en) * 1965-09-03 1968-06-11 Allan R. Day Substituted 1, 4-diazabicyclo [4. 4. 9] decanes
GB8518236D0 (en) * 1985-07-19 1985-08-29 Beecham Group Plc Compounds
AU5291793A (en) * 1992-09-24 1994-04-12 National Institutes Of Health Aralkyl diazabicycloalkane derivatives for cns disorders
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
WO1996010570A1 (en) * 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
ES2274795T3 (es) * 1999-07-19 2007-06-01 Merck Frosst Canada Ltd. Pirazinonas, composiciones que contienen tales compuestos.

Also Published As

Publication number Publication date
EP1275647A1 (fr) 2003-01-15
PT1275647E (pt) 2004-03-31
HUP0202282A2 (hu) 2003-03-28
EA200200663A1 (ru) 2003-02-27
KR20030007159A (ko) 2003-01-23
EA005160B1 (ru) 2004-12-30
CN1397557A (zh) 2003-02-19
NO20023345D0 (no) 2002-07-11
US6992085B2 (en) 2006-01-31
MXPA02006699A (es) 2005-08-16
JP2003064081A (ja) 2003-03-05
HK1050682A1 (en) 2003-07-04
HUP0202282A3 (en) 2003-11-28
DE60200089D1 (de) 2003-12-18
DE60200089T2 (de) 2004-09-09
ATE254124T1 (de) 2003-11-15
DK1275647T3 (da) 2004-03-15
US20030195216A1 (en) 2003-10-16
ES2210219T3 (es) 2004-07-01
ZA200205596B (en) 2003-03-27
HU0202282D0 (enExample) 2002-09-28
TR200302001T4 (tr) 2004-01-21
PL355034A1 (en) 2003-01-13
FR2827288B1 (fr) 2003-10-31
CA2394027A1 (fr) 2003-01-12
AR036166A1 (es) 2004-08-18
EP1275647B1 (fr) 2003-11-12
AU2002300094B2 (en) 2007-06-14
BR0202681A (pt) 2003-05-06
FR2827288A1 (fr) 2003-01-17
CN1197863C (zh) 2005-04-20
KR100485020B1 (ko) 2005-04-25
NZ520120A (en) 2004-03-26
NO20023345L (no) 2003-01-13
NO322966B1 (no) 2006-12-18
SI1275647T1 (en) 2004-02-29
JP3950018B2 (ja) 2007-07-25

Similar Documents

Publication Publication Date Title
EP1499589B1 (fr) Derives de n-¬phenyl(piperidin-2-yl)methyl|benzamide, leur preparation et leur application en therapeutique
EP1680418B1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP0666258A1 (en) Indolylcycloaklanylamin- und Indolylcycloalkenylamine derivatives, their preparation and their use as anti-migraine agents
JP2002530276A (ja) 新規なピペラジンおよびピペリジン化合物
FR2667068A1 (fr) Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2476088A2 (fr) Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique
CA2394027C (fr) Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2674849A1 (fr) Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
CN1440398A (zh) 用作抗惊厥药的取代2－苯并[c]呋喃酮
CA1228359A (fr) Procede de preparation de nouveaux derives de la quinoleine
EP0841330B1 (fr) Nouveaux dérivés aminométhyl hétérocycliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
HUP0100926A2 (hu) Benzilpiperazinil- és benzilpiperidiniletanon-származékok, előállításuk és alkalmazásuk dopamin D4 receptor antagonistaként
EP0591027A1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique
US6958396B2 (en) 8-{4-[3-(5-fluoro-1H-indol-3-YL)-Propyl]-Piperazin-1-YL}-2-methyl-4H-Benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
RU2222535C2 (ru) 3-тетрагидропиридин-4-илиндолы для лечения психотических нарушений
CN1128030A (zh) 具有中枢神经系统活性的杂环胺
JP2001521935A (ja) ３−アミノアルキルアミノ−２ｈ−１，４−ベンゾキシアジン及び３−アミノアルキルアミノ−２ｈ−１，４−ベンゾチアジン：ドーパミン受容体サブタイプ特定の配位子
FR2822153A1 (fr) Nouveaux derives d'indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2918002B2 (ja) アミノメチル アリール化合物；ドーパミンレセプター亜型選択性リガンド
EP2277882A1 (fr) Composés pipéridiniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
FR2953515A1 (fr) Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2346506C (fr) Derives d'aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone comme agonistes du recepteur 5-ht1
US20060094764A1 (en) Cyanothiophenes, their preparation and their use in pharmaceutical compositions
JPH0550499B2 (enExample)
TWI225487B (en) New phenylpiperazines

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed